A radioactive patch worn for roughly four to five days is now available to selected skin-cancer patients at UC San Diego Health. The health system said Wednesday that Jacobs Medical Center is the first U.S. hospital to offer CivaDerm, an FDA-cleared brachytherapy device designed to deliver a physician-prescribed radiation dose continuously while the patient is away from the clinic.
Brachytherapy places a radiation source at or near a tumor. CivaDerm uses palladium-103 inside a flexible bandage, with shielding on one side to direct the dose toward the treated tissue. A care team applies the device once and removes it after the course is complete. That schedule differs from UC San Diego's existing high-dose-rate brachytherapy program, which can require visits twice a week for about five weeks, and from external-beam treatment delivered daily over several weeks.
The shorter calendar does not make the device a universal replacement. UC San Diego described it as an option for select early-stage basal cell and squamous cell carcinomas, the two most common forms of skin cancer. It is not a treatment for melanoma. Initial use will focus on lesions of the scalp, neck, arms, legs and trunk; anatomy and treatment planning can make a facial lesion unsuitable.
Candidacy also depends on more than a diagnosis. Clinicians must evaluate a tumor's type, size, depth and location, along with the patient's health and ability to follow radiation-safety instructions. UC San Diego said people wearing the bandage must observe precautions that include keeping about six feet from others. The source announcement did not publish a complete eligibility checklist or comparative outcome data for the hospital's first patients.
For a patient who lives far from La Jolla, uses a mobility aid or cannot make repeated appointments, the practical difference can be substantial. One placement and one removal reduce travel, parking and time away from work or caregiving. Those access gains are the clearest immediate advantage. Whether the device is preferable medically remains an individual decision, because surgery and established radiation methods have different indications, risks and follow-up needs.
The Food and Drug Administration distinction matters. A cleared device has gone through a regulatory pathway that permits marketing for its intended use; the term does not mean every patient should receive it or that it has proved superior to every alternative. UC San Diego's release announces clinical availability, not the results of a randomized comparison. The health system did not disclose price, insurance coverage, capacity or how many people it expects to treat.
Non-melanoma skin cancer is common, but incidence estimates require care because many cases are not captured in central cancer registries. UC San Diego cited an American Cancer Society estimate of about 5.4 million basal and squamous cell cancers diagnosed each year in roughly 3.3 million Americans. That large burden explains interest in treatments that can preserve outcomes while reducing the number of clinic visits, but it does not establish how many patients qualify for this device.
The program adds another route rather than closing the choice. Patients still need pathology, staging, radiation planning, safety counseling and follow-up after the bandage comes off. As UC San Diego begins using CivaDerm, the useful measures will be who is eligible, whether courses are completed as prescribed, what side effects occur and how local control compares over time. The new feature is the delivery method: several days of continuous, localized radiation in a wearable form.